Drug Developer Lays Out Terms For $87M IPO
Danish drug developer Ascendis Pharma A/S outlined in a U.S. Securities and Exchange Commission filing on Friday the proposal for its initial public offering, which is expected to draw up to...To view the full article, register now.
Already a subscriber? Click here to view full article